SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Alseres Pharmaceuticals
ALSE 0.005000.0%Oct 18 5:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Jorgen Jensen3/20/2006 1:59:26 PM
   of 975
 
Boston Life Sciences Ends ALTROPANE(R) POET-1 Phase III Trial Early to Evaluate Full Data Set
Monday March 20, 1:00 pm ET
Company Believes Trial May Have Already Enrolled Enough Subjects to Achieve Statistical Significance

HOPKINTON, Mass., March 20 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (Nasdaq: BLSI - News), a development-stage biotechnology company focused on diagnostic and therapeutic products for diseases of the central nervous system, has notified the U.S. Food and Drug Administration (FDA) that it has elected to terminate its current Special Protocol Assessment (SPA) and end its Phase III, Parkinson's or Essential Tremor (POET-1) trial for ALTROPANE earlier than planned in order to analyze the full set of data for efficacy. No safety issues have been identified in this trial. Based on the previous performance of ALTROPANE and BLSI's monitoring of non-blinded data from the approximately 200 patients enrolled in the POET-1 trial to date, the company believes it may have already enrolled enough subjects in the trial to evaluate the efficacy of ALTROPANE single photon emission computed tomography (SPECT) imaging in the differentiation of Parkinsonian Syndrome tremors from non- Parkinsonian or Essential tremors.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News